FDA Approval of Continuous Glucose Monitors Marks Milestone for Metabolic Health

The Society for Metabolic Health Practitioners (SMHP) celebrates the FDA’s approval of Dexcom’s Stelo Continuous Glucose Monitors (CGM) for over-the-counter sales, a milestone that empowers individuals to better understand and manage their metabolic health.

This advancement removes barriers for everyone, regardless of whether they have type 1 or type 2 diabetes. Now, anyone can access information about their metabolic health earlier and without a prescription, empowering them to take control of their health. Dr. Tro Kalayjian, an SMHP board member and metabolic health advocate, emphasizes the transformative potential of CGMs, stating, “This will help people make more empowered choices about foods especially as it relates to eliminating foods high in sugar or processed carbohydrates.”

Doug Reynolds, President of the SMHP, highlights how this aligns with the organization’s mission of promoting evidence-based nutritional approaches to improve metabolic health. “The availability of CGMs over-the-counter further bolsters our commitment to educating and empowering individuals with the tools they need to succeed long-term. With CGMs, individuals will gain the freedom to understand how food affects their bodies, empowering them to make better lifestyle choices.” says Reynolds.

With CGM technology now more accessible, the SMHP anticipates a positive shift in how individuals manage their metabolic health, fostering a future where proactive health management is the norm.

You can read the complete FDA approval letter here.